Human Papilloma Virus HPV Test and Pap SmearTest Market - Global Forecast to 2030
商品番号 : SMB-24847
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年10月 |
| ページ数 | 282 |
| 図表数 | 366 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
HPV検査およびパップテスト市場 – 製品とサービス（消耗品、器具）、検査の種類（フォローアップ、併用検査、一次HPV）、技術（MDx、細胞診）、用途（膣、子宮頸部）、ケア環境別 – 2030年までの世界予測
HPV検査およびパップテスト市場は、2025年には推定24億4,000万米ドル規模と評価され、2030年には39億4,000万米ドルに達すると予測されています。予測期間中の年平均成長率（CAGR）は10.0%です。子宮頸がんに対する意識の高まりと適時スクリーニングの重要性が、HPV検査およびパップテスト市場を大きく押し上げています。公衆衛生キャンペーン、政府のスクリーニングイニシアチブ、および教育的取り組みにより、女性はHPV感染に関連するリスクと早期発見の重要性についてより多くの情報を得るようになっています。この意識の高まりは、定期的なスクリーニングプログラムへの参加増加につながり、HPV検査とパップテストの両方の需要を直接的に刺激しています。医療提供者、擁護団体、および非営利団体からの支援により、女性のヘルスケアの重要な要素としての予防スクリーニングがさらに強化されています。より多くの女性がスクリーニングに関する情報とリソースにアクセスできるようになるにつれて、検査数は着実に増加し、持続的な市場成長を促進し、世界中の子宮頸がん発生率の低減におけるHPV検査とパップテストの役割を強化すると予想されます。
この調査レポートでは、HPV（ヒトパピローマウイルス）検査およびパップテスト市場を、製品およびサービス（消耗品、機器、サービス）、検査タイプ（HPV検査（プライマリHPV検査、併用検査、フォローアップHPV検査）およびパップテスト）、技術（分子診断、免疫診断、細胞診）、用途（子宮頸がんスクリーニングおよび膣がんスクリーニング）、ケア環境（病院、診断研究所、医師の診療所およびクリニック）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東およびアフリカ）別に分類しています。
本レポートは、HPV（ヒトパピローマウイルス）検査およびパップテスト市場の成長に影響を与える主要な要因（促進要因、制約要因、機会、課題など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、各社の事業概要、ソリューション、主要戦略、買収、契約に関する洞察を提供しています。また、HPV検査およびパップテスト市場エコシステムにおける新興企業の競合分析も本レポートに含まれています。
本レポートは、HPV（ヒトパピローマウイルス）検査およびパップテスト市場全体および各サブセグメントの収益数値の近似値に関する情報を提供し、市場リーダーおよび新規参入企業にとって役立ちます。また、本レポートは、関係者が競争環境を理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。さらに、本レポートは、関係者が市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供するのにも役立ちます。
The HPV testing and Pap test market is valued at an estimated USD 2.44 billion in 2025 and is projected to reach USD 3.94 billion by 2030, at a CAGR of 10.0% during the forecast period. The rising awareness of cervical cancer and the importance of timely screening is significantly boosting the HPV testing and Pap test market. Public health campaigns, government screening initiatives, and educational efforts are making women more informed about the risks associated with HPV infection and the critical role of early detection. This heightened awareness is leading to greater participation in routine screening programs, directly fueling the demand for both HPV and Pap tests. Support from healthcare providers, advocacy groups, and non-profit organizations further reinforces preventive screening as a key component of women’s healthcare. As more women gain access to information and resources about screening, test volumes are expected to rise steadily, driving sustained market growth and strengthening the role of HPV and Pap testing in reducing cervical cancer incidence worldwide.
“By product & service, the consumables segment dominated the HPV testing and Pap test market in 2024.”
Based on product & service, the HPV testing and Pap test market is segmented into consumables, instruments, and services. In 2024, consumables accounted for the largest share of the market. This dominance is driven by the widespread use of reagents, collection kits, and assay consumables that are essential for both HPV and Pap testing on a recurring basis. The increasing adoption of HPV screening programs, coupled with the expansion of cervical cancer prevention initiatives, has created steady demand for these products. Consumables play a critical role in ensuring accuracy and reproducibility of test results, which is reinforced by regulatory guidelines that mandate standardized testing protocols. Moreover, the growing shift toward molecular-based HPV assays and automated cytology platforms has further increased the reliance on specialized consumables. The recurring nature of consumable usage, compared to one-time investments in instruments, positions this segment as the largest revenue contributor in the HPV testing and Pap test market.
“By application, the vaginal cancer screening segment is projected to achieve the highest growth during the forecast period.”
By application, the HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. While cervical cancer screening currently accounts for the majority of testing volumes due to its high prevalence and established screening guidelines, vaginal cancer screening is expected to witness the fastest growth during the forecast period. This growth is primarily driven by increasing awareness of vaginal cancers, improvements in diagnostic sensitivity of HPV tests, and a gradual expansion of screening practices beyond cervical cancer. Rising research efforts and clinical recommendations supporting HPV testing for broader gynecologic cancer detection are also contributing to the adoption of vaginal cancer screening. Although it remains a relatively smaller segment today, the potential for early detection and improved patient outcomes is likely to accelerate demand, positioning vaginal cancer screening as a key growth area in the HPV testing and Pap test market.
“The Asia Pacific is projected to be the fastest-growing regional market during the forecast period.”
The market for HPV testing and Pap tests is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to experience the fastest growth in the HPV testing and Pap test market during the forecast period. Rapid urbanization, improving healthcare infrastructure, and increasing access to diagnostic facilities are expanding screening opportunities across the region. Government-led initiatives and public health campaigns in countries such as China, India, and Southeast Asian nations are actively promoting cervical cancer awareness and early detection programs. The rising prevalence of HPV infections and growing concerns about women’s health are driving the adoption of HPV and Pap testing. Additionally, market players are introducing cost-effective and high-throughput testing solutions tailored to local needs, further accelerating adoption. The combination of expanding healthcare access, regulatory support, and rising patient awareness positions the Asia Pacific as the fastest-growing regional segment in the global HPV testing and Pap test market.
Breakdown of the profiles of primary participants in the HPV testing and Pap test market:
- By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
- By Designation: C-level Executives (27%), Director-level Executives (18%), and Others (55%)
- By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)
The key players in the HPV testing and Pap test market are Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Danaher Corporation (US), Abbott (US), Seegene Inc. (South Korea), SD Biosensor, INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, Inc. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain), Atila Biosystems (US), Yaneng BIOscience (Shenzhen) Co., Ltd. (China), Xiamen Zeesan Biotech Co., Ltd. (China), Advanced Molecular Diagnostics (AMD) (UK), Mylab Discovery Solutions Pvt. Ltd. (India), Sacace Biotechnologies Srl (Italy), Jiangsu Mole Bioscience Co., Ltd. (China), HANGZHOU ALLTEST BIOTECH CO., LTD. (China), Hangzhou Tongzhou Biotechnology Co., Ltd. (China), and Nanjing Liming Biological Products Co., Ltd. (China).
Research Coverage:
This research report categorizes the HPV testing and Pap test market by product & service (consumables, instruments, and services), test type [HPV testing (primary HPV testing, co-testing, and follow-up HPV testing) and Pap tests], technology (molecular diagnostics, immunodiagnostics, and cytology), application (cervical cancer screening and vaginal cancer screening), care setting (hospitals, diagnostic laboratories, and physicians’ offices & clinics), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the HPV testing and Pap test market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. Competitive analysis of upcoming startups in the HPV testing and Pap test market ecosystem is covered in this report.
Reasons to buy this report:
The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall HPV testing and Pap test market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (rising HPV cases and subsequent increase in cervical cancer, growing awareness of cervical cancer screening programs, and increasing R&D funding initiatives on cervical cancer prevention), opportunities (regulatory guidelines for cervical cancer screening and innovative improvements in HPV tests), restraints (growing awareness of HPV vaccinations), and challenges (uncertain reimbursement scenario, stringent regulatory & legal requirements, and operational barriers) influencing the growth of the HPV testing and Pap test market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches/approvals in the HPV testing and Pap test market.
- Market Development: Comprehensive information about lucrative markets across varied regions
- Market Diversification: Exhaustive information about products, untapped geographies, recent developments, and investments in the HPV testing and Pap test market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), and Danaher Corporation (US).
Table of Contents
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 29
1.3.2 INCLUSIONS AND EXCLUSIONS 30
1.3.3 YEARS CONSIDERED 31
1.4 CURRENCY CONSIDERED 31
1.5 STAKEHOLDERS 31
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.2 RESEARCH APPROACH 33
2.2.1 SECONDARY DATA 34
2.2.1.1 Key secondary sources 34
2.2.1.2 Key data from secondary sources 34
2.2.2 PRIMARY DATA 35
2.2.2.1 Primary sources 36
2.2.2.2 Key data from primary sources 36
2.2.2.3 Key industry insights 38
2.2.2.4 Breakdown of primary interviews 38
2.3 MARKET SIZE ESTIMATION 39
2.3.1 BOTTOM-UP APPROACH 40
2.3.1.1 Company revenue estimation approach 40
2.3.1.2 Presentations of companies and primary interviews 40
2.3.1.3 Growth forecast 41
2.3.1.4 CAGR projections 41
2.3.1.5 Epidemiology-based test volume estimation approach 42
2.3.2 TOP-DOWN APPROACH 42
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 44
2.5 MARKET SHARE ASSESSMENT 45
2.6 RESEARCH ASSUMPTIONS 45
2.7 RESEARCH LIMITATIONS 45
2.8 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 52
4.1 HPV TESTING AND PAP TEST MARKET OVERVIEW 52
4.2 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 52
4.3 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2025 VS. 2030 53
4.4 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2025 VS. 2030 53
4.5 HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2025 VS. 2030 54
4.6 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2025 VS. 2030 54
4.7 HPV TESTING AND PAP TEST MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
5.2.1 DRIVERS 57
5.2.1.1 Rising HPV cases and subsequent increase in cervical cancer 57
5.2.1.2 Growing awareness about cervical cancer screening programs 58
5.2.1.3 Increasing R&D funding initiatives on cervical cancer prevention 59
5.2.2 RESTRAINTS 59
5.2.2.1 Growing awareness and adoption of HPV vaccination 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Regulatory guidelines for cervical cancer screening 60
5.2.3.2 Innovative improvements in HPV tests 61
5.2.4 CHALLENGES 61
5.2.4.1 Uncertain reimbursement scenario 61
5.2.4.2 Stringent regulatory and legal requirements 62
5.2.4.3 Operational barriers 62
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 62
5.4 PRICING ANALYSIS 63
5.4.1 AVERAGE SELLING PRICE TREND OF HPV AND PAP TESTS 63
5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 64
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION 65
5.5 VALUE CHAIN ANALYSIS 65
5.6 SUPPLY CHAIN ANALYSIS 67
5.7 ECOSYSTEM ANALYSIS 68
5.8 INVESTMENT AND FUNDING SCENARIO 69
5.9 TECHNOLOGY ANALYSIS 70
5.9.1 KEY TECHNOLOGIES 70
5.9.1.1 Molecular diagnostics 70
5.9.2 COMPLEMENTARY TECHNOLOGIES 71
5.9.2.1 Cytology 71
5.9.3 ADJACENT TECHNOLOGIES 71
5.9.3.1 Immunodiagnostics 71
5.10 KEY CONFERENCES AND EVENTS, 2025–2026 72
5.11 PATENT ANALYSIS 73
5.12 TRADE ANALYSIS 75
5.12.1 IMPORT DATA FOR HS CODE 3822 75
5.12.2 EXPORT DATA FOR HS CODE 3822 76
5.13 CASE STUDY ANALYSIS 77
5.13.1 CASE STUDY 1: UTILIZATION OF HUMAN PAPILLOMAVIRUS TESTING FOR CERVICAL CANCER SCREENING IN THAILAND 77
5.13.2 CASE STUDY 2: IMPLEMENTATION OF HUMAN PAPILLOMAVIRUS PRIMARY SCREENING OF CERVICAL CANCER IN BRITISH COLUMBIA 78
5.13.3 CASE STUDY 3: COMPARATIVE EVALUATION OF HPV SELF-SAMPLING IN INDIA 78
5.14 REGULATORY LANDSCAPE 79
5.14.1 REGULATORY FRAMEWORK 79
5.14.1.1 NORTH AMERICA 79
5.14.1.1.1 US 79
5.14.1.1.2 Canada 79
5.14.1.2 Europe 79
5.14.1.2.1 Germany 80
5.14.1.2.2 UK 80
5.14.1.2.3 France 81
5.14.1.2.4 Italy 81
5.14.1.3 Asia Pacific 81
5.14.1.3.1 China 81
5.14.1.3.2 Japan 81
5.14.1.3.3 India 82
5.14.1.4 Latin America 82
5.14.1.4.1 Brazil 82
5.14.1.4.2 Mexico 83
5.14.1.5 Middle East 83
5.14.1.6 Africa 83
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
5.15 PORTER’S FIVE FORCES ANALYSIS 85
5.15.1 BARGAINING POWER OF BUYERS 87
5.15.2 BARGAINING POWER OF SUPPLIERS 87
5.15.3 THREAT OF NEW ENTRANTS 87
5.15.4 THREAT OF SUBSTITUTES 87
5.15.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 88
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
5.16.2 BUYING CRITERIA 88
5.17 IMPACT OF AI/GENERATIVE AI ON HPV TESTING AND PAP TEST MARKET 89
5.17.1 INTRODUCTION 89
5.17.2 MARKET POTENTIAL OF AI 90
5.17.3 AI USE CASES 91
5.17.4 KEY COMPANIES IMPLEMENTING AI 91
5.17.5 FUTURE OF AI IN HPV TESTING AND PAP TEST MARKET 92
5.18 IMPACT OF 2025 US TARIFFS ON HPV TESTING AND PAP TEST MARKET 92
5.18.1 INTRODUCTION 92
5.18.2 KEY TARIFF RATES 93
5.18.3 PRICE IMPACT ANALYSIS 93
5.18.4 IMPACT ON COUNTRY/REGION 94
5.18.4.1 North America 94
5.18.4.2 Europe 94
5.18.4.3 Asia Pacific 94
5.18.5 IMPACT ON END-USE INDUSTRIES 94
5.18.5.1 Hospitals 94
5.18.5.2 Diagnostic laboratories 95
5.18.5.3 Physicians’ offices & clinics 95
6 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE 96
6.1 INTRODUCTION 97
6.2 CONSUMABLES 97
6.2.1 RECURRENT PURCHASES OF ASSAYS & KITS TO DRIVE GROWTH 97
6.3 INSTRUMENTS 99
6.3.1 INCREASING ADOPTION OF AUTOMATED DIAGNOSTIC SYSTEMS
TO DRIVE GROWTH 99
6.4 SERVICES 100
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE DEMAND 100
7 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE 102
7.1 INTRODUCTION 103
7.2 HPV TESTING 103
7.2.1 PRIMARY HPV TESTING 107
7.2.1.1 Test sensitivity and accuracy to drive growth 107
7.2.2 FOLLOW-UP HPV TESTING 109
7.2.2.1 Irregular Pap test results to drive adoption 109
7.2.3 CO-TESTING 112
7.2.3.1 Co-testing to drive rapid detection results for cervical cancer 112
7.3 PAP TESTS 114
7.3.1 RISING CASES OF FALSE-NEGATIVE TESTS TO RESTRAIN MARKET 114
8 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY 117
8.1 INTRODUCTION 118
8.2 MOLECULAR DIAGNOSTICS 118
8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN HPV DETECTION TO DRIVE MARKET GROWTH 118
8.3 IMMUNODIAGNOSTICS 121
8.3.1 COST BENEFITS OF IMMUNOASSAYS TO BOOST DEMAND 121
8.4 CYTOLOGY 124
8.4.1 AUTOMATION AND DIGITAL IMAGING TO DRIVE ADOPTION 124
9 HPV TESTING AND PAP TEST MARKET, BY APPLICATION 127
9.1 INTRODUCTION 128
9.2 CERVICAL CANCER SCREENING 128
9.2.1 RISING INCIDENCE OF CERVICAL CANCER TO DRIVE MARKET 128
9.3 VAGINAL CANCER SCREENING 133
9.3.1 LIMITED SCREENING TESTS TO RESTRAIN MARKET 133
10 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING 136
10.1 INTRODUCTION 137
10.2 HOSPITALS 137
10.2.1 ADVANCED TECHNOLOGIES AND EQUIPPED FACILITIES TO DRIVE MARKET 137
10.3 DIAGNOSTIC LABORATORIES 140
10.3.1 INCREASING OUTSOURCING OF DIAGNOSTIC TESTS TO LABORATORIES TO DRIVE MARKET 140
10.4 PHYSICIANS’ OFFICES & CLINICS 143
10.4.1 RAPID AND EFFICIENT RESULTS TO SUPPORT MARKET GROWTH 143
11 HPV TESTING AND PAP TEST MARKET, BY REGION 146
11.1 INTRODUCTION 147
11.2 NORTH AMERICA 148
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 152
11.2.2 US 153
11.2.2.1 Rising government initiatives for cervical cancer testing to expedite growth 153
11.2.3 CANADA 155
11.2.3.1 Growing awareness of cervical cancer screening to support growth 155
11.3 EUROPE 157
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 161
11.3.2 GERMANY 161
11.3.2.1 Established healthcare infrastructure and rising healthcare spending to promote growth 161
11.3.3 UK 163
11.3.3.1 Rising focus on research projects for specific cancers to contribute to growth 163
11.3.4 FRANCE 165
11.3.4.1 High incidence of cervical cancer and associated investments in genomics to stimulate growth 165
11.3.5 ITALY 167
11.3.5.1 Growing acceptance of molecular-based diagnostic tests for cervical cancer screening to boost market 167
11.3.6 SPAIN 169
11.3.6.1 Increasing research on cancer diagnostics to accelerate growth 169
11.3.7 REST OF EUROPE 171
11.4 ASIA PACIFIC 174
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 178
11.4.2 CHINA 178
11.4.2.1 Growing public access to modern healthcare to propel market 178
11.4.3 JAPAN 181
11.4.3.1 Rising demand for technologically advanced cervical cancer screening tests to facilitate growth 181
11.4.4 INDIA 183
11.4.4.1 Expanding healthcare access and high cervical cancer burden to drive market 183
11.4.5 REST OF ASIA PACIFIC 185
11.5 LATIN AMERICA 188
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 191
11.5.2 BRAZIL 192
11.5.2.1 Universal healthcare access to speed up growth 192
11.5.3 MEXICO 194
11.5.3.1 Improved access to healthcare to sustain growth 194
11.5.4 REST OF LATIN AMERICA 196
11.6 MIDDLE EAST & AFRICA 199
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 202
11.6.2 SAUDI ARABIA 202
11.6.2.1 Rising government healthcare expenditure to augment growth 202
11.6.3 UAE 205
11.6.3.1 Increasing emphasis on healthy lifestyles and quality of life to encourage growth 205
11.6.4 REST OF MIDDLE EAST & AFRICA 207
12 COMPETITIVE LANDSCAPE 210
12.1 INTRODUCTION 210
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 210
12.2.1 OVERVIEW OF MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HPV TESTING AND PAP TEST MARKET 210
12.3 REVENUE ANALYSIS, 2022–2024 212
12.4 MARKET SHARE ANALYSIS, 2024 213
12.5 COMPANY VALUATION AND FINANCIAL METRICS 215
12.5.1 COMPANY VALUATION 215
12.5.2 FINANCIAL METRICS 216
12.6 BRAND/PRODUCT COMPARISON 216
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 217
12.7.1 STARS 217
12.7.2 EMERGING LEADERS 217
12.7.3 PERVASIVE PLAYERS 217
12.7.4 PARTICIPANTS 217
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 219
12.7.5.1 Company footprint 219
12.7.5.2 Region footprint 220
12.7.5.3 Product & service footprint 220
12.7.5.4 Test type footprint 221
12.7.5.5 Technology footprint 221
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 222
12.8.1 PROGRESSIVE COMPANIES 222
12.8.2 RESPONSIVE COMPANIES 222
12.8.3 DYNAMIC COMPANIES 222
12.8.4 STARTING BLOCKS 222
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 224
12.8.5.1 Detailed list of key startups/SMEs 224
12.8.5.2 Competitive benchmarking of key startups/SMEs 225
12.9 COMPETITIVE SCENARIO 226
12.9.1 PRODUCT LAUNCHES AND APPROVALS 226
12.9.2 DEALS 227
12.9.3 EXPANSIONS 228
13 COMPANY PROFILES 229
13.1 KEY PLAYERS 229
13.1.1 HOLOGIC, INC. 229
13.1.1.1 Business overview 229
13.1.1.2 Products offered 230
13.1.1.3 MnM view 231
13.1.1.3.1 Right to win 231
13.1.1.3.2 Strategic choices 231
13.1.1.3.3 Weaknesses and competitive threats 231
13.1.2 BECTON, DICKINSON AND COMPANY (BD) 232
13.1.2.1 Business overview 232
13.1.2.2 Products offered 233
13.1.2.3 Recent developments 234
13.1.2.3.1 Product launches and approvals 234
13.1.2.3.2 Deals 234
13.1.2.3.3 Expansions 235
13.1.2.4 MnM view 236
13.1.2.4.1 Right to win 236
13.1.2.4.2 Strategic choices 236
13.1.2.4.3 Weaknesses and competitive threats 236
13.1.3 F. HOFFMANN-LA ROCHE LTD. 237
13.1.3.1 Business overview 237
13.1.3.2 Products offered 238
13.1.3.3 Recent developments 239
13.1.3.3.1 Product launches and approvals 239
13.1.3.4 MnM view 239
13.1.3.4.1 Right to win 239
13.1.3.4.2 Strategic choices 240
13.1.3.4.3 Weaknesses and competitive threats 240
13.1.4 QIAGEN 241
13.1.4.1 Business overview 241
13.1.4.2 Products offered 242
13.1.4.3 Recent developments 243
13.1.4.3.1 Expansions 243
13.1.4.4 MnM view 243
13.1.4.4.1 Right to win 243
13.1.4.4.2 Strategic choices 244
13.1.4.4.3 Weaknesses and competitive threats 244
13.1.5 DANAHER CORPORATION 245
13.1.5.1 Business overview 245
13.1.5.2 Products offered 246
13.1.5.3 MnM view 247
13.1.5.3.1 Right to win 247
13.1.5.3.2 Strategic choices 247
13.1.5.3.3 Weaknesses and competitive threats 247
13.1.6 ABBOTT 248
13.1.6.1 Business overview 248
13.1.6.2 Products offered 249
13.1.6.3 Recent developments 250
13.1.6.3.1 Product launches and approvals 250
13.1.6.3.2 Deals 250
13.1.7 SEEGENE INC. 251
13.1.7.1 Business overview 251
13.1.7.2 Products offered 252
13.1.7.3 Recent developments 253
13.1.7.3.1 Product launches and approvals 253
13.1.7.3.2 Deals 253
13.1.8 SD BIOSENSOR, INC. 255
13.1.8.1 Business overview 255
13.1.8.2 Products offered 256
13.1.9 SANSURE BIOTECH INC. 257
13.1.9.1 Business overview 257
13.1.9.2 Products offered 257
13.1.9.3 Recent developments 258
13.1.9.3.1 Product launches and approvals 258
13.1.9.3.2 Deals 258
13.1.10 ACON LABORATORIES, INC. 259
13.1.10.1 Business overview 259
13.1.10.2 Products offered 259
13.2 OTHER PLAYERS 260
13.2.1 MOLBIO DIAGNOSTICS LIMITED 260
13.2.2 AB ANALITICA S.R.L. 261
13.2.3 CERTEST BIOTEC 262
13.2.4 ATILA BIOSYSTEMS 263
13.2.5 TELLGEN CORPORATION 264
13.2.6 DAAN GENE CO., LTD. 265
13.2.7 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD. 266
13.2.8 ANATOLIA GENEWORKS 267
13.2.9 YANENG BIOSCIENCE (SHENZHEN) CO., LTD. 268
13.2.10 XIAMEN ZEESAN BIOTECH CO., LTD. 269
13.2.11 ADVANCED MOLECULAR DIAGNOSTICS (AMD) 270
13.2.12 MYLAB DISCOVERY SOLUTIONS PVT. LTD. 270
13.2.13 SACACE BIOTECHNOLOGIES SRL 271
13.2.14 JIANGSU MOLE BIOSCIENCE CO., LTD. 272
13.2.15 HANGZHOU ALLTEST BIOTECH CO., LTD. 272
13.2.16 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD. 273
13.2.17 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD. 273
14 APPENDIX 274
14.1 DISCUSSION GUIDE 274
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 278
14.3 CUSTOMIZATION OPTIONS 280
14.4 RELATED REPORTS 280
14.5 AUTHOR DETAILS 281
LIST OF TABLES
TABLE 1 HPV TESTING AND PAP TEST MARKET: INCLUSIONS AND EXCLUSIONS 30
TABLE 2 HPV TESTING AND PAP TEST MARKET: KEY DATA FROM PRIMARY SOURCES 36
TABLE 3 HPV TESTING AND PAP TEST MARKET: RISK ASSESSMENT ANALYSIS 46
TABLE 4 ESTIMATED NUMBER OF NEW CASES OF CERVICAL CANCER, BY REGION,
2022 VS. 2030 58
TABLE 5 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, 2023–2025 (USD) 63
TABLE 6 AVERAGE SELLING PRICING TREND OF HPV AND PAP TESTS, BY REGION (USD) 64
TABLE 7 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY KEY PLAYER,
2023–2025 (USD) 64
TABLE 8 AVERAGE SELLING PRICE TREND OF HPV TESTS, BY REGION, 2023–2025 (USD) 65
TABLE 9 HPV TESTING AND PAP TEST MARKET: ROLE OF COMPANIES IN ECOSYSTEM 69
TABLE 10 HPV TESTING AND PAP TEST MARKET: KEY CONFERENCES AND EVENTS,
2025–2026 72
TABLE 11 HPV TESTING AND PAP TEST MARKET: LIST OF MAJOR PATENTS, 2023–2025 74
TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2024 (USD MILLION) 76
TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2024 (USD MILLION) 77
TABLE 14 CLASSIFICATION OF IVD DEVICES IN EUROPE 80
TABLE 15 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 82
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 84
TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 21 HPV TESTING AND PAP TEST MARKET: IMPACT OF PORTER’S FIVE FORCES 86
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT &
SERVICE (%) 88
TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 89
TABLE 24 RECIPROCAL TARIFF RATES ADJUSTED BY US 93
TABLE 25 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 97
TABLE 26 KEY CONSUMABLES AVAILABLE IN MARKET 98
TABLE 27 HPV TESTING AND PAP TEST CONSUMABLES MARKET, BY REGION,
2023–2030 (USD MILLION) 99
TABLE 28 KEY INSTRUMENTS AVAILABLE IN MARKET 100
TABLE 29 HPV TESTING AND PAP TEST INSTRUMENTS MARKET, BY REGION,
2023–2030 (USD MILLION) 100
TABLE 30 HPV TESTING AND PAP TEST SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 101
TABLE 31 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 103
TABLE 32 KEY HPV TESTING PRODUCTS AVAILABLE IN MARKET 104
TABLE 33 HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 104
TABLE 34 HPV TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 35 NORTH AMERICA: HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 105
TABLE 36 EUROPE: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 37 ASIA PACIFIC: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 38 LATIN AMERICA: HPV TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 39 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 106
TABLE 40 PRIMARY HPV TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 107
TABLE 41 NORTH AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 42 EUROPE: PRIMARY HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 43 ASIA PACIFIC: PRIMARY HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 108
TABLE 44 LATIN AMERICA: PRIMARY HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 45 MIDDLE EAST & AFRICA: PRIMARY HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 109
TABLE 46 FOLLOW-UP HPV TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 110
TABLE 47 NORTH AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 48 EUROPE: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 110
TABLE 49 ASIA PACIFIC: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 50 LATIN AMERICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 51 MIDDLE EAST & AFRICA: FOLLOW-UP HPV TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 111
TABLE 52 CO-TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 112
TABLE 53 NORTH AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 54 EUROPE: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 55 ASIA PACIFIC: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 56 LATIN AMERICA: CO-TESTING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 57 MIDDLE EAST & AFRICA: CO-TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 114
TABLE 58 KEY PAP TESTS AVAILABLE IN MARKET 114
TABLE 59 PAP TESTS MARKET, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 60 NORTH AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 61 EUROPE: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 62 ASIA PACIFIC: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 63 LATIN AMERICA: PAP TESTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116
TABLE 64 MIDDLE EAST & AFRICA: PAP TESTS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 116
TABLE 65 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 118
TABLE 66 KEY MOLECULAR DIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET 119
TABLE 67 HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 68 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 69 EUROPE: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 70 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 71 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 72 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 73 KEY IMMUNODIAGNOSTIC-BASED PRODUCTS AVAILABLE IN MARKET 122
TABLE 74 HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 122
TABLE 75 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 76 EUROPE: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 77 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 78 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 79 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 80 HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY REGION,
2023–2030 (USD MILLION) 125
TABLE 81 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 82 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 83 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 84 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 85 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CYTOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 86 HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 128
TABLE 87 KEY HPV TESTING AND PAP TESTS FOR CERVICAL CANCER SCREENING
AVAILABLE IN MARKET 130
TABLE 88 HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING,
BY REGION, 2023–2030 (USD MILLION) 131
TABLE 89 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 90 EUROPE: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 91 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 92 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 93 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR CERVICAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 94 KEY HPV TESTING AND PAP TESTS FOR VAGINAL CANCER SCREENING
AVAILABLE IN MARKET 133
TABLE 95 HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING,
BY REGION, 2023–2030 (USD MILLION) 133
TABLE 96 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL
CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 97 EUROPE: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 98 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 99 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 100 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR VAGINAL CANCER SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 101 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 137
TABLE 102 HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY REGION,
2023–2030 (USD MILLION) 138
TABLE 103 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 104 EUROPE: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 105 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 106 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 107 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 108 HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2023–2030 (USD MILLION) 141
TABLE 109 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 110 EUROPE: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 111 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 112 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 113 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 114 HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS,
BY REGION, 2023–2030 (USD MILLION) 144
TABLE 115 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’
OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 116 EUROPE: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 117 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 118 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 119 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET FOR PHYSICIANS’ OFFICES & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 120 PROJECTED CERVICAL CANCER CASES, BY COUNTRY, 2022 VS. 2030 147
TABLE 121 HPV TESTING AND PAP TEST MARKET, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 122 TOTAL NUMBER OF HPV TESTS CONDUCTED, BY REGION,
2023–2030 (MILLION UNIT) 148
TABLE 123 TOTAL NUMBER OF PAP TESTS CONDUCTED, BY REGION,
2023–2030 (MILLION UNIT) 148
TABLE 124 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 150
TABLE 125 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 126 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 150
TABLE 127 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 151
TABLE 128 NORTH AMERICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 151
TABLE 129 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 151
TABLE 130 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 152
TABLE 131 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 152
TABLE 132 US: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 153
TABLE 133 US: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 154
TABLE 134 US: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 154
TABLE 135 US: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 154
TABLE 136 US: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 155
TABLE 137 CANADA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 156
TABLE 138 CANADA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 139 CANADA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 156
TABLE 140 CANADA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 157
TABLE 141 CANADA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 157
TABLE 142 EUROPE: HPV TESTING AND PAP TEST MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 158
TABLE 143 EUROPE: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE,
2023–2030 (USD MILLION) 159
TABLE 144 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 159
TABLE 145 EUROPE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 159
TABLE 146 EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 160
TABLE 147 EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 160
TABLE 148 EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 160
TABLE 149 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 162
TABLE 150 GERMANY: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 162
TABLE 151 GERMANY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 162
TABLE 152 GERMANY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 163
TABLE 153 GERMANY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 163
TABLE 154 UK: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 164
TABLE 155 UK: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 164
TABLE 156 UK: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 164
TABLE 157 UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 165
TABLE 158 UK: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 165
TABLE 159 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 166
TABLE 160 FRANCE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 161 FRANCE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 166
TABLE 162 FRANCE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 167
TABLE 163 FRANCE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 167
TABLE 164 ITALY: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 168
TABLE 165 ITALY: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 168
TABLE 166 ITALY: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 168
TABLE 167 ITALY: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 169
TABLE 168 ITALY: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 169
TABLE 169 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 170
TABLE 170 SPAIN: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 170
TABLE 171 SPAIN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 170
TABLE 172 SPAIN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 171
TABLE 173 SPAIN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 171
TABLE 174 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 172
TABLE 175 REST OF EUROPE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 172
TABLE 176 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 173
TABLE 177 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 173
TABLE 178 REST OF EUROPE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 173
TABLE 179 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 175
TABLE 180 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 176
TABLE 181 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 176
TABLE 182 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 176
TABLE 183 ASIA PACIFIC: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 177
TABLE 184 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 177
TABLE 185 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 177
TABLE 186 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 178
TABLE 187 CHINA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 179
TABLE 188 CHINA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 179
TABLE 189 CHINA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 180
TABLE 190 CHINA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 180
TABLE 191 CHINA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 180
TABLE 192 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 181
TABLE 193 JAPAN: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 194 JAPAN: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 182
TABLE 195 JAPAN: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 182
TABLE 196 JAPAN: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 183
TABLE 197 INDIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 184
TABLE 198 INDIA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 184
TABLE 199 INDIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 184
TABLE 200 INDIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 185
TABLE 201 INDIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 185
TABLE 202 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 186
TABLE 203 REST OF ASIA PACIFIC: HPV TESTING MARKET, BY TYPE,
2023–2030 (USD MILLION) 186
TABLE 204 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 187
TABLE 205 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 206 REST OF ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 187
TABLE 207 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 189
TABLE 208 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 189
TABLE 209 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET,
BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 189
TABLE 210 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 190
TABLE 211 LATIN AMERICA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 212 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 190
TABLE 213 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 191
TABLE 214 LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 191
TABLE 215 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 192
TABLE 216 BRAZIL: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 217 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 193
TABLE 218 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 193
TABLE 219 BRAZIL: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 194
TABLE 220 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 195
TABLE 221 MEXICO: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 195
TABLE 222 MEXICO: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 195
TABLE 223 MEXICO: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 196
TABLE 224 MEXICO: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 196
TABLE 225 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 197
TABLE 226 REST OF LATIN AMERICA: HPV TESTING MARKET, BY TYPE,
2023–2030 (USD MILLION) 197
TABLE 227 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 198
TABLE 228 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198
TABLE 229 REST OF LATIN AMERICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 198
TABLE 230 MIDDLE EAST & AFRICA: KEY MACROECONOMIC INDICATORS 199
TABLE 231 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 232 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 200
TABLE 233 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 200
TABLE 234 MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE,
2023–2030 (USD MILLION) 201
TABLE 235 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 201
TABLE 236 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 201
TABLE 237 MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING, 2023–2030 (USD MILLION) 202
TABLE 238 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 203
TABLE 239 SAUDI ARABIA: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 203
TABLE 240 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 204
TABLE 241 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 204
TABLE 242 SAUDI ARABIA: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 204
TABLE 243 UAE: HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 205
TABLE 244 UAE: HPV TESTING MARKET, BY TYPE, 2023–2030 (USD MILLION) 206
TABLE 245 UAE: HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 206
TABLE 246 UAE: HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 206
TABLE 247 UAE: HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2023–2030 (USD MILLION) 207
TABLE 248 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 208
TABLE 249 REST OF MIDDLE EAST & AFRICA: HPV TESTING MARKET, BY TYPE,
2023–2030 (USD MILLION) 208
TABLE 250 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 208
TABLE 251 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 209
TABLE 252 REST OF MIDDLE EAST & AFRICA: HPV TESTING AND PAP TEST MARKET,
BY CARE SETTING, 2023–2030 (USD MILLION) 209
TABLE 253 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN
HPV TESTING AND PAP TEST MARKET, JANUARY 2022−SEPTEMBER 2025 210
TABLE 254 HPV TESTING AND PAP TEST MARKET: DEGREE OF COMPETITION 214
TABLE 255 HPV TESTING AND PAP TEST MARKET: REGION FOOTPRINT 220
TABLE 256 HPV TESTING AND PAP TEST MARKET: PRODUCT & SERVICE FOOTPRINT 220
TABLE 257 HPV TESTING AND PAP TEST MARKET: TEST TYPE FOOTPRINT 221
TABLE 258 HPV TESTING AND PAP TEST MARKET: TECHNOLOGY FOOTPRINT 221
TABLE 259 HPV TESTING AND PAP TEST MARKET: DETAILED LIST OF KEY STARTUPS/SMES 224
TABLE 260 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY PRODUCT & SERVICE AND TEST TYPE 225
TABLE 261 HPV TESTING AND PAP TEST MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY REGION 225
TABLE 262 HPV TESTING AND PAP TEST MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 226
TABLE 263 HPV TESTING AND PAP TEST MARKET: DEALS, JANUARY 2022–SEPTEMBER 2025 227
TABLE 264 HPV TESTING AND PAP TEST MARKET: EXPANSIONS,
JANUARY 2022–SEPTEMBER 2025 228
TABLE 265 HOLOGIC, INC.: COMPANY OVERVIEW 229
TABLE 266 HOLOGIC, INC.: PRODUCTS OFFERED 230
TABLE 267 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 232
TABLE 268 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 233
TABLE 269 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 234
TABLE 270 BECTON, DICKINSON AND COMPANY (BD): DEALS,
JANUARY 2022–SEPTEMBER 2025 234
TABLE 271 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS,
JANUARY 2022–SEPTEMBER 2025 235
TABLE 272 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 237
TABLE 273 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 238
TABLE 274 F. HOFFMAN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 239
TABLE 275 QIAGEN: COMPANY OVERVIEW 241
TABLE 276 QIAGEN: PRODUCTS OFFERED 242
TABLE 277 QIAGEN: EXPANSIONS, JANUARY 2022–SEPTEMBER 2025 243
TABLE 278 DANAHER CORPORATION: COMPANY OVERVIEW 245
TABLE 279 DANAHER CORPORATION: PRODUCTS OFFERED 246
TABLE 280 ABBOTT: COMPANY OVERVIEW 248
TABLE 281 ABBOTT: PRODUCTS OFFERED 249
TABLE 282 ABBOTT: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–SEPTEMBER 2025 250
TABLE 283 ABBOTT: DEALS, JANUARY 2022–SEPTEMBER 2025 250
TABLE 284 SEEGENE INC.: COMPANY OVERVIEW 251
TABLE 285 SEEGENE INC.: PRODUCTS OFFERED 252
TABLE 286 SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–SEPTEMBER 2025 253
TABLE 287 SEEGENE INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 253
TABLE 288 SD BIOSENSOR, INC.: COMPANY OVERVIEW 255
TABLE 289 SD BIOSENSOR, INC.: PRODUCTS OFFERED 256
TABLE 290 SANSURE BIOTECH INC.: COMPANY OVERVIEW 257
TABLE 291 SANSURE BIOTECH INC.: PRODUCTS OFFERED 257
TABLE 292 SANSURE BIOTECH INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–SEPTEMBER 2025 258
TABLE 293 SANSURE BIOTECH INC.: DEALS, JANUARY 2022–SEPTEMBER 2025 258
TABLE 294 ACON LABORATORIES, INC.: COMPANY OVERVIEW 259
TABLE 295 ACON LABORATORIES, INC.: PRODUCTS OFFERED 259
TABLE 296 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW 260
TABLE 297 AB ANALITICA S.R.L.: COMPANY OVERVIEW 261
TABLE 298 CERTEST BIOTEC: COMPANY OVERVIEW 262
TABLE 299 ATILA BIOSYSTEMS: COMPANY OVERVIEW 263
TABLE 300 TELLGEN CORPORATION: COMPANY OVERVIEW 264
TABLE 301 DAAN GENE CO., LTD.: COMPANY OVERVIEW 265
TABLE 302 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD.: COMPANY OVERVIEW 266
TABLE 303 ANATOLIA GENEWORKS: COMPANY OVERVIEW 267
TABLE 304 YANENG BIOSCIENCE (SHENZHEN) CO., LTD.: COMPANY OVERVIEW 268
TABLE 305 XIAMEN ZEESAN BIOTECH CO., LTD.: COMPANY OVERVIEW 269
TABLE 306 ADVANCED MOLECULAR DIAGNOSTICS (AMD): COMPANY OVERVIEW 270
TABLE 307 MYLAB DISCOVERY SOLUTIONS PVT. LTD.: COMPANY OVERVIEW 270
TABLE 308 SACACE BIOTECHNOLOGIES SRL: COMPANY OVERVIEW 271
TABLE 309 JIANGSU MOLE BIOSCIENCE CO., LTD.: COMPANY OVERVIEW 272
TABLE 310 HANGZHOU ALLTEST BIOTECH CO., LTD.: COMPANY OVERVIEW 272
TABLE 311 HANGZHOU TONGZHOU BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 273
TABLE 312 NANJING LIMING BIOLOGICAL PRODUCTS CO., LTD.: COMPANY OVERVIEW 273
LIST OF FIGURES
FIGURE 1 HPV TESTING AND PAP TEST MARKET SEGMENTATION AND REGIONAL SCOPE 29
FIGURE 2 HPV TESTING AND PAP TEST MARKET: RESEARCH DESIGN METHODOLOGY 33
FIGURE 3 PRIMARY SOURCES 36
FIGURE 4 KEY INDUSTRY INSIGHTS 38
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 38
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 39
FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 9 EPIDEMIOLOGY-BASED TEST VOLUME ESTIMATION APPROACH 42
FIGURE 10 HPV TESTING AND PAP TEST MARKET: TOP-DOWN APPROACH 43
FIGURE 11 DATA TRIANGULATION METHODOLOGY 44
FIGURE 12 HPV TESTING AND PAP TEST MARKET: RESEARCH ASSUMPTIONS 45
FIGURE 13 HPV TESTING AND PAP TEST MARKET, BY PRODUCT & SERVICE,
2025 VS. 2030 (USD MILLION) 47
FIGURE 14 HPV TESTING AND PAP TEST MARKET, BY TEST TYPE,
2025 VS. 2030 (USD MILLION) 48
FIGURE 15 HPV TESTING AND PAP TEST MARKET, BY TECHNOLOGY,
2025 VS. 2030(USD MILLION) 48
FIGURE 16 HPV TESTING AND PAP TEST MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 49
FIGURE 17 HPV TESTING AND PAP TEST MARKET, BY CARE SETTING,
2025 VS. 2030 (USD MILLION) 50
FIGURE 18 HPV TESTING AND PAP TEST MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 50
FIGURE 19 RISING CASES OF HPV AND INCREASING R&D INITIATIVES ON CERVICAL
CANCER SCREENING TO DRIVE MARKET 52
FIGURE 20 CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52
FIGURE 21 HPV TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 53
FIGURE 22 MOLECULAR DIAGNOSTICS SEGMENT TO SHOWCASE LARGEST MARKET SHARE DURING FORECAST PERIOD 53
FIGURE 23 CERVICAL CANCER SCREENING SEGMENT TO ACCOUNT FOR
LARGEST MARKET SHARE DURING FORECAST PERIOD 54
FIGURE 24 HOSPITALS SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2030 54
FIGURE 25 NORTH AMERICAN MARKET TO ACCOUNT FOR LARGEST SHARE
DURING FORECAST PERIOD 55
FIGURE 26 HPV TESTING AND PAP TEST MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN HPV TESTING AND PAP TEST MARKET 63
FIGURE 28 HPV TESTING AND PAP TEST MARKET: VALUE CHAIN ANALYSIS 66
FIGURE 29 HPV TESTING AND PAP TEST MARKET: SUPPLY CHAIN ANALYSIS 68
FIGURE 30 HPV TESTING AND PAP TEST MARKET: ECOSYSTEM ANALYSIS 68
FIGURE 31 HPV TESTING AND PAP TEST MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025 70
FIGURE 32 HPV TESTING AND PAP TEST MARKET: PATENT ANALYSIS,
JANUARY 2015–DECEMBER 2024 73
FIGURE 33 HPV TESTING AND PAP TEST MARKET: PORTER’S FIVE FORCES ANALYSIS 86
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 88
FIGURE 35 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 88
FIGURE 36 MARKET POTENTIAL OF AI IN HPV TESTING AND PAP TEST MARKET 90
FIGURE 37 NORTH AMERICA: HPV TESTING AND PAP TEST MARKET SNAPSHOT 149
FIGURE 38 ASIA PACIFIC: HPV TESTING AND PAP TEST MARKET SNAPSHOT 175
FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND
PAP TEST MARKET, 2022–2024 212
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HPV TESTING AND
PAP TEST MARKET, 2024 213
FIGURE 41 YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA
OF KEY VENDORS 215
FIGURE 42 EV/EBITDA OF KEY VENDORS 216
FIGURE 43 HPV TESTING AND PAP TEST MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 216
FIGURE 44 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 218
FIGURE 45 HPV TESTING AND PAP TEST MARKET: COMPANY FOOTPRINT 219
FIGURE 46 HPV TESTING AND PAP TEST MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 223
FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT 230
FIGURE 48 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 233
FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 238
FIGURE 50 QIAGEN: COMPANY SNAPSHOT 242
FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT 246
FIGURE 52 ABBOTT: COMPANY SNAPSHOT 249
FIGURE 53 SEEGENE INC.: COMPANY SNAPSHOT 252
FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT 255
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- データセンターUPS市場規模、シェア、動向、2030年までの世界予測 2025-10-31
- 高純度ガス市場規模、シェア、動向、2030年までの世界予測 2025-10-30
- 動物用生物学的製剤市場規模、シェア、動向、2030年までの世界予測 2025-10-30
- エンジニアリング樹脂向け難燃剤市場規模、シェア、動向、2030年までの世界予測 2025-10-29
- アプリケーションモダナイゼーションサービス市場規模、シェア、動向、2031年までの世界予測 2025-10-29